Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines’ immunogenicity

References

• Kampman K, Jarvis M. American Society of AddictionMedicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):1–11. doi:10.1097/ADM.0000000000000166.
   PubMed Web of Science ®Google Scholar
• Grant JE, Potenza MN, Weinstein A, Gorelick DA. Introduction to behavioral addictions. Am J Drug Alcohol Abuse. 2010;36(5):233–41. doi:10.3109/00952990.2010.491884.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crimes. UNODC world drug report 2021: pandemic effects ramp up drug risks, as youth underestimate cannabis dangers; 2021 [accessed 2022 Apr 10]. https://www.unodc.org/unodc/press/releases/2021/June/unodc-world-drug-report-2021_-pandemic-effects-ramp-up-drug-risks–as-youth-underestimate-cannabis-dangers.html.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Statistical Bulletin; 2021 [accessed 2022 Apr 10]. https://www.emcdda.europa.eu/data/stats2021_en.
   Google Scholar
• Shen X, Kosten TR. Immunotherapy for drug abuse. CNS Neurol Disord Drug Targets. 2011;10(8):876–79. doi:10.2174/187152711799219352.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Rosen M, Bond J, Settles M, Roberts JSC, Shields J, Jack L, Fox B. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine. 2002;20(7–8):1196–204. doi:10.1016/S0264-410X(01)00425-X.
   PubMed Web of Science ®Google Scholar
• Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther. 2012;91(1):60–70. doi:10.1038/clpt.2011.281.
   PubMed Web of Science ®Google Scholar
• Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR. Vaccines for cocaine abuse. Hum Vaccin. 2009;5(4):194–99. doi:10.4161/hv.5.4.7457.
   PubMed Web of Science ®Google Scholar
• Pulendran B, PS A, DT O. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–75. doi:10.1038/s41573-021-00163-y.
   PubMed Web of Science ®Google Scholar
• Mentzer AJ, O’Connor D, Pollard AJ, Hill AVS. Searching for the human genetic factors standing in the way of universally effective vaccines. Philos Trans R Soc Lond B Biol Sci. 2015;370(1671):20140341. doi:10.1098/rstb.2014.0341.
   PubMed Web of Science ®Google Scholar
• Crouse B, Robinson C, Huseby Kelcher A, Laudenbach M, Abrahante JE, Pravetoni M. Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders. NPJ Vaccines. 2020;5(1):99. doi:10.1038/s41541-020-00247-7.
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Laudenbach M, Tucker AM, Jenkins MK, Pravetoni M. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. J Immunol Methods. 2014;405:74–86. doi:10.1016/j.jim.2014.01.010.
   PubMed Web of Science ®Google Scholar
• Linnik JE, Egli A. Impact of host genetic polymorphisms on vaccine induced antibody response. Hum Vaccin Immunother. 2016;12(4):907–15. doi:10.1080/21645515.2015.1119345.
   PubMed Web of Science ®Google Scholar
• Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005;58(2):158–64. doi:10.1016/j.biopsych.2005.04.032.
   PubMed Web of Science ®Google Scholar
• Kinsey BM, Kosten TR, Orson FM. Anti-cocaine vaccine development. Expert Rev Vaccines. 2010;9(9):1109–14. doi:10.1586/erv.10.102.
   PubMed Web of Science ®Google Scholar
• Deng SX, de Prada P, Landry DW. Anticocaine catalytic antibodies. J Immunol Methods. 2002;269(1–2):299–310. doi:10.1016/S0022-1759(02)00237-5.
   PubMed Web of Science ®Google Scholar
• Hossain MK, Hassanzadeganroudsari M, Nurgali K, Apostolopoulos V. Vaccine development against methamphetamine drug addiction. Expert Rev Vaccines. 2020;19(12):1105–14. doi:10.1080/14760584.2020.1857738.
   PubMed Web of Science ®Google Scholar
• Miller ML, Aarde SM, Moreno AY, Creehan KM, Janda KD, Taffe MA. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug Alcohol Depend. 2015;153:29–36. doi:10.1016/j.drugalcdep.2015.06.014.
   PubMed Web of Science ®Google Scholar
• Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol. 2014;77(2):368–74. doi:10.1111/bcp.12115.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49(1):57–71. doi:10.1146/annurev.pharmtox.48.113006.094742.
   PubMedGoogle Scholar
• Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs. 2007;16(11):1775–83. doi:10.1517/13543784.16.11.1775.
   PubMed Web of Science ®Google Scholar
• Esterlis I, Hannestad JO, Perkins E, Bois F, D’Souza DC, Tyndale RF, Seibyl JP, Hatsukami DM, Cosgrove KP, O’Malley SS. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry. 2013;170(4):399–407. doi:10.1176/appi.ajp.2012.12060793.
   PubMed Web of Science ®Google Scholar
• Neil Stowe G, Schlosburg JE, Vendruscolo LF, Edwards S, Misra K K, Schulteis G S, Zakhari J, Koob GF, Janda KD. Developing a vaccine against multiple psychoactive targets: a case study of heroin. 2011;10(8):865–75. doi:10.2174/187152711799219316.
   Google Scholar
• Schlosburg JE, Vendruscolo LF, Bremer PT, Lockner JW, Wade CL, Nunes AAK, Stowe GN, Edwards S, Janda KD, Koob GF. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A. 2013;110(22):9036–41. doi:10.1073/pnas.1219159110.
   PubMed Web of Science ®Google Scholar
• Columbia University Irving Medical Center. Experimental opioid vaccine being tested at Columbia; 2021 [accessed 2022 Apr 10]. https://www.cuimc.columbia.edu/news/experimental-opioid-vaccine-being-tested-columbia.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry. 2010;67(1):59–65. doi:10.1016/j.biopsych.2009.08.031.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014;140:42–47. doi:10.1016/j.drugalcdep.2014.04.003.
   PubMed Web of Science ®Google Scholar
• Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. 2009;66(10):1116–23. doi:10.1001/archgenpsychiatry.2009.128.
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim REF, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89(3):392–99. doi:10.1038/clpt.2010.317.
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Rennard S, Jorenby D, FIORE M, Koopmeiners J, Devos A, Horwith G, Pentel P. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers [published correction appears in Clin Pharmacol Ther. 2006 Apr; 79 (4):396]. Clin Pharmacol Ther 2005;78(5):456–67. doi:10.1016/j.clpt.2005.08.007.
   PubMed Web of Science ®Google Scholar
• Havermans A, Vuurman EF, van den Hurk J, Hoogsteder P, van Schayck OCP. Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task. Addiction. 2014;109(8):1260–67. doi:10.1111/add.12577.
   PubMed Web of Science ®Google Scholar
• Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, van Schayck OCP. Efficacy of the nicotine vaccine 3′-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction. 2014;109(8):1252–59. doi:10.1111/add.12573.
   PubMed Web of Science ®Google Scholar
• Wagena EJ, de Vos A, Horwith G, van Schayck C. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res. 2008;10(1):213–18. doi:10.1080/14622200701704921.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Heggen E, Giljam H, Lagerback P-A, Tonnesen P, Wikingsson LD, Lindblom N, de Villiers S, Svensson TH, Fagerstrom K-O. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res. 2013;15(9):1492–501. doi:10.1093/ntr/ntt003.
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, Bangala Y, Guessous I, Müller P, Willers J, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008;3(6):e2547. doi:10.1371/journal.pone.0002547.
   PubMed Web of Science ®Google Scholar
• Mukhin AG. Improving the efficacy of anti-nicotine immunotherapy (PETNic002). ClinicalTrials.gov identifier: NCT01280968; 2013 [accessed 2022 Apr 10]. https://clinicaltrials.gov/ct2/show/NCT01280968.
   Google Scholar
• Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Müller P, Bachmann MF. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031–40. doi:10.1002/eji.200526285.
   PubMed Web of Science ®Google Scholar
• Goniewicz ML, Delijewski M. Nicotine vaccines to treat tobacco dependence. Hum Vaccin Immunother. 2013;9(1):13–25. doi:10.4161/hv.22060.
   PubMed Web of Science ®Google Scholar
• Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine [published correction appears in Drug Des Devel Ther. 2011; 5:487]. Drug Des Devel Ther 2011;5:211–24. doi:10.2147/DDDT.S10033.
   PubMed Web of Science ®Google Scholar
• Ohia-Nwoko O, Kosten TA, Haile CN. Animal models and the development of vaccines to treat substance use disorders. Int Rev Neurobiol. 2016;126:263–91.
   PubMed Web of Science ®Google Scholar
• Nabi Biopharmaceuticals. News release: Nabi biopharmaceuticals announces results of second nicvax(r) phase iii clinical trial; 2011 [accessed 2022 Apr 10]. https://www.fiercebiotech.com/biotech/nabi-biopharmaceuticals-announces-results-of-second-nicvax-r-phase-iii-clinical-trial-0.
   Google Scholar
• Kantak KM. Vaccines against drugs of abuse: a viable treatment option? Drugs. 2003;63(4):341–52. doi:10.2165/00003495-200363040-00001.
   PubMed Web of Science ®Google Scholar